|Bid||290.01 x 1000|
|Ask||302.00 x 800|
|Day's Range||290.72 - 297.29|
|52 Week Range||287.66 - 442.00|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||16.49|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Is Regeneron Pharmaceuticals Holdings (REGN) a great pick from the value investor's perspective right now? Read on to know more.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) has received ample support from multiple catalysts this week. On Tuesday, the company announced FDA approval for its prefilled Eylea syringe. The good news ...
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 13) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) NextCure ...
An experimental Ebola drug developed by Regeneron Pharmaceuticals has shown promising results. But Wall Street hasn’t rewarded the stock because of it.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) shares were trading higher Tuesday after Eylea, its product to treat retinal conditions, snagged another approval. What Happened Regeneron said Tuesday ahead ...
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
Two of four experimental Ebola drugs being tested in Congo seem to be saving lives, international health authorities announced Monday. The preliminary findings prompted an early halt to a major study on the drugs and a decision to prioritize their use in the African country, where a yearlong outbreak has killed more than 1,800 people. The early results mark “some very good news,” said Dr. Anthony Fauci of the U.S. National Institutes of Health, which helped fund the study.
Scientists are a step closer to being able to cure the deadly Ebola haemorrhagic fever after two experimental drugs showed survival rates of as much as 90% in a clinical trial in Congo. Two experimental drugs - an antibody cocktail called REGN-EB3 developed by Regeneron and a monoclonal antibody called mAb114 - will now be offered to all patients infected with the viral disease in an ongoing outbreak in the Democratic Republic of Congo (DRC).
Regeneron Pharmaceuticals Inc said on Monday its experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death, in a trial evaluating four treatments for infections caused by the deadly virus. The company said the trial was ended early because its therapy, REGN-EB3, elicited a "highly statistically significant result" compared to Mapp's ZMapp, which was considered a standard-of-care treatment.
The drug developer's revenue growth was fueled by double-digit increases in medications that treat macular degeneration, eczema and asthma.
Regeneron stock inched up Tuesday after the biotech company topped Wall Street's second-quarter expectations on strong Eylea sales as its Sanofi antibody collaboration became profitable.
Regeneron (REGN) tops on Q2 earnings and sales in the second quarter on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.
Shares of Regeneron Pharmaceuticals Inc. rose 2.2% in premarket trade Tuesday after the company reported second-quarter earnings that beat analysts' expectations. Profit in the latest quarter fell to $193 million, or $1.68 a share, from $551 million, or $4.82 a share, a year ago. Adjusted EPS was $6.02 a share, topping the FactSet consensus of $5.42 a share. Revenue came in at $1.934 billion, compared with $1.608 billion in the year-earlier quarter, beating the FactSet consensus of $1.804 billion. Regeneron derives revenue from its own discovered products and from collaborations with Sanofi and Bayer AG . Revenue from Regeneron's own products grew to $1.205 billion in the latest quarter -- which included U.S. sales of $1.16 billion from the company's eye drug Eylea -- from $996.4 million in the year-earlier quarter. Sales of Eylea outside the U.S. came to $715.3 million and were booked by Bayer. Revenue from Regeneron's Sanofi collaboration rose to $349.1 million from $237.8 million a year ago, while revenue from the Bayer collaboration grew to $289 million from $262.9 million a year ago. Shares of Regeneron have fallen 20% in the year to date through Monday, while the S&P 500 has gained 13.5%.